Form 4: Athyrium Entities Receive Warrants in Biora Therapeutics Following Forbearance Agreement

Athyrium Opportunities III Acquisition LP and Athyrium Opportunities III Co-Invest 1 LP receive warrants to purchase Biora Therapeutics common stock in exchange for forbearing from exercising certain rights under convertible notes.

Summary

• Athyrium Opportunities III Acquisition LP and Athyrium Opportunities III Co-Invest 1 LP entered into a letter agreement with Biora Therapeutics, Inc.
• In exchange for forbearing from exercising certain rights and remedies against Biora Therapeutics under the terms of the Company's 11.00% / 13.00% Convertible Senior Secured Notes due 2028, Biora issued warrants to Athyrium Opportunities III Acquisition 2 LP and Co-Invest LP.
• Athyrium Opportunities III Acquisition 2 LP received warrants to purchase 110,479 shares of Biora's common stock.
• Athyrium Opportunities III Co-Invest 1 LP received warrants to purchase 346,771 shares of Biora's common stock.
• The warrants have an exercise price of $0.63 per share.
• The warrants are exercisable from July 3, 2024, until July 3, 2028.
• The warrants are subject to exercise limitations, including a beneficial ownership limitation of 49.9% of the outstanding common stock.

Sentiment

Score: 5

Explanation: Neutral sentiment. The agreement provides Biora with short-term relief but dilutes existing shareholders. The long-term impact depends on Biora's ability to improve its financial performance and increase its stock price.

Positives

• Biora Therapeutics secured an agreement from Athyrium to forbear from exercising certain rights, potentially providing the company with more financial flexibility.
• The issuance of warrants, rather than cash, preserves Biora's cash reserves.

Negatives

• The issuance of warrants dilutes existing shareholders' equity.
• The exercise of warrants could increase the number of outstanding shares, potentially impacting earnings per share.

Risks

• The warrants are subject to exercise limitations, including a beneficial ownership limitation of 49.9%, which could impact their value.
• The value of the warrants is dependent on the future performance of Biora Therapeutics' common stock.
• The potential exercise of the warrants could create downward pressure on the stock price.

Future Outlook

The document does not contain specific forward-looking statements from Biora Therapeutics regarding its future performance beyond the details of the warrant agreement.

Industry Context

This type of agreement, where warrants are issued in exchange for forbearance on debt enforcement, is relatively common in situations where a company is facing financial challenges. It allows the company to avoid immediate default while providing the debt holder with potential upside if the company's stock price improves.

Comparison to Industry Standards

• Similar transactions can be seen with other biotech companies facing liquidity constraints, such as [hypothetical company A] issuing warrants to debt holders in exchange for extending debt maturities.
• The warrant exercise price of $0.63 is a key factor, and its attractiveness will depend on Biora's stock performance relative to its peers, such as [hypothetical company B] and [hypothetical company C], which have similar market caps and product pipelines.

Stakeholder Impact

• Shareholders will experience potential dilution from the issuance of warrants.
• Creditors (Athyrium) receive warrants, providing potential upside in exchange for forbearing on their rights.
• The company gains financial flexibility in the short term.

Key Dates

Keywords

warrants, Athyrium, Biora Therapeutics, forbearance, common stock, convertible notes